Testing various antiplatelet strategies in psoriasis to improve vascular health
Active Grant Awarded Last action
- Award ID
- R01HL188015
- Recipient
-
New York University UEI M5SZJ6VHUHN8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $845,590
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 4% complete
- Place of performance
- New York, NY 10016, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded New York University, doing business as New York University School of Medicine, $845,590 on September 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837), as Grant R01HL188015. The funded project, "Testing Various Antiplatelet Strategies in Psoriasis to Improve Vascular Health," tests whether antiplatelet therapy attenuates platelet-driven endovascular damage in psoriasis, a condition the project cites as carrying roughly 50% increased cardiovascular disease risk compared with matched controls. Aim 1 determines the effect of antiplatelet therapy on the endovascular phenotype in psoriasis and plans to enroll 54 patients with a history of moderate-to-severe psoriasis. The period of performance ends May 31, 2031, and the place of performance is New York, NY 10016.
Description
- Abstract
- Background: psoriasis is a common chronic inflammatory skin disease associated with a ~50% increased risk of cardiovascular (CV) disease compared to matched controls. Randomized placebo-controlled trials assessing biologic therapies have failed to show that targetting psoriatic skin disease reduces CV risk. These negative studies suggest targeting the immunologic drivers of psoriatic skin inflammation may not be enough to reduce CV risk, and there is a need to identify alternative therapeutic targets and strategies. Preliminary data: using brachial vein endothelial harvesting, our lab identified over-expression of endothelial pro-atherosclerotic transcripts (e.g., IL-1Β, IL-8, CCL2) in psoriasis (VS. Controls). Platelets are intermediaries implicated in early atherosclerosis and thrombosis. We found that psoriasis platelets (VS. Controls) are activated and aggregate in response to adenosine diphosphate (ADP) to a greater extent than in controls and independent of psoriasis treatment and severity. Psoriasis platelets overexpress pro-inflammatory transcripts and stimulate endothelial-derived inflammatory transcripts upon CO-incubation with cultured endothelial cells. Hypothesis: antiplatelet therapy reduces atherothrombosis but increases bleeding and is thus infrequently used for primary CV prevention. In psoriasis, prior clinical trials to reduce CV risk have not focused on platelets' central role in mediating early atherosclerosis and their interaction with the vascular endothelium. We will test the overarching hypothesis that in psoriasis, platelets are a key pathogenic mediator promoting endovascular damage in psoriasis which can be attenuated by antiplatelet therapy. Aim 1: determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis. We will enroll 54 patients with a history of moderate-to-severe psoriasis on stable (or no) therapy without clinical CV disease and randomize them in a cross-over design to 1 month each of the ADP receptor antagonist clopidogrel (75 MG), low-dose aspirin (81 MG), or placebo daily. We will assess the impact of antiplatelet therapy on: 1) a composite of brachial vein endothelial pro-inflammatory/atherosclerotic transcripts (primary endpoint); 2) brachial vein endothelial cell RNA sequencing; 3) flow-mediated vasodilation. Aim 2: quantify the differential impact of antiplatelet therapy in psoriasis patients on platelet activation, platelet effector cell properties, and the platelet transcriptome in psoriasis. As secondary endpoints from the proposed clinical trial, we will measure in psoriasis patients before and after antiplatelet therapy: 1) platelet activation (e.g. leukocyte-platelet aggregates, platelet surface expression of P- selectin and PAC-1), 2) the platelet transcriptome, and 3) the platelet effector cell properties to induce pro- inflammatory transcript expression on cultured endothelial cells (in vitro). Objective: this study will provide insight into early atherosclerosis mechanisms and suggest a new treatment paradigm to mitigate atherothrombosis and platelet-mediated vascular damage in psoriasis.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $845,590 |
Quick answers
Who received award R01HL188015?
R01HL188015 was awarded to New York University by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R01HL188015 worth?
$845,590 has been obligated on R01HL188015.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award